B20 Health Conference – Antimicrobial Resistance: Opportunities and Challenges

18 May 2017 Gasometer, EUREF-Campus 17, 10829 Berlin

18 May 2017


15:00 to 16:30


Gasometer, EUREF-Campus 17, 10829 Berlin


This event has now passed. To browse our upcoming events click here.

The B20 Health Initiative aims at providing an exchange platform between the global health care industry, governments, international organizations and civil society to jointly drive change towards innovative health systems.

On 18th May 2017 the B20 Health Initiative hosts the B20 Health Conference: Resilient Health Systems – Shaping the Future of Health Care Together.

In accordance with the B20 Germany motto, the B20 Health Conference focusses on the role global businesses can play in delivering resilient, responsible and responsive health systems. At the conference, the final communiqué of the B20 Health Initiative will officially be handed over to a representative of the G20 Health Ministers.

IFPMA will take part in a panel discussion on antimicrobial resistance.



Antimicrobial Resistance: Opportunities and Challenges


Benjamin Grosch Partner & Managing Director Berlin, Boston Consulting Group

Dr. Benjamin Grosch is a core member of The Boston Consulting Group’s Health Care and People & Organization practices. He is a designated expert on digital in health care, on biopharma along the entire value chain, and on health care systems, payers health insurance, and hospitals. He is a member of BCG’s management team for Germany and Austria.
Benjamin joined the firm in December 2003 in Munich and worked in the New York and Washington offices during 2006 and 2007.
Benjamin supports clients in the pharmaceuticals and medical technology industries on issues of strategy, digital health, processes and organization, digital marketing and sales. He has extensive experience working with leading German payers on projects including medical cost reduction, digital processes, and channel mix and customer service.

Thomas B. Cueni Director General, IFPMA

Thomas B. Cueni is Director General of IFPMA since 1 February 2017. Prior to joining IFPMA he was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland. For many years Thomas Cueni has been involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA, where he most recently served as Vice-Chair of the European Markets Committee and association representative on the Board. He represented the industry on the EU High Level Pharmaceutical Forum, was Chairman of EFPIA’s Economic and Social Policy Committee and Chairman of the EFPIA Task Force on the EU Commission’s Pharmaceutical Sector Inquiry. Thomas Cueni also represented Interpharma, which he successfully transformed from the association of Swiss Rx companies to the association of pharmaceutical research companies in Switzerland, on the Council of IFPMA.
Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”, and he served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basle, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).

Manica Balasegaram Director, GARDP Operations, DNDi

Dr Manica Balasegaram, who is a medical doctor by training, started his career in internal and emergency medicine in the UK and in Australia, then joining Médecins sans Frontières as a field physician in Sub-Saharan Africa and Southern Asia. He was later appointed Head of the MSF Manson Unit, before initially joining DNDi as Head of Leishmaniasis – a position he left four years ago to become the MSF Access Campaign’s Executive Director. His experience spans clinical and public health practice in neglected and infectious diseases, clinical trials and drug development, international work on health policy and access to medicines and involvement in a variety of expert technical committees. He rejoined DNDi in June 2016 as Director of the Global Antibiotic Research and Development Partnership, a joint DNDi-WHO initiative.